Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibition and treatment of hepatitis B virus and flavivirus by helioxanthin and its analogs

A yellow fever virus and compound technology, applied in antiviral agents, medical preparations containing active ingredients, drug combinations, etc., can solve problems that do not involve anti-HBV compounds

Inactive Publication Date: 2002-03-27
YALE UNIV +3
View PDF55 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] So far, no studies of this kind have involved the development of anti-HBV compounds from the xanthoids of saline

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibition and treatment of hepatitis B virus and flavivirus by helioxanthin and its analogs
  • Inhibition and treatment of hepatitis B virus and flavivirus by helioxanthin and its analogs
  • Inhibition and treatment of hepatitis B virus and flavivirus by helioxanthin and its analogs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0053] The following definitions are used in the context of this specification to describe the invention.

[0054] The term "patient" is used in the context of this specification to describe an animal, preferably a human, to whom a method of treatment, including prophylactic therapy, with a composition of the invention is provided. For the treatment of those infections, diseases or disease conditions that are specific to a particular animal, such as a human patient, the term patient refers to the particular animal.

[0055] The term "hepatitis B virus" (HBV) is used to describe the virus that produces viral hepatitis B in humans (serum hepatitis virus). This is a viral disease with a long incubation period (approximately 50-160 days), in contrast to hepatitis A virus (the infectious hepatitis virus), which has a short incubation period. The virus is usually transmitted by injection of infected blood or blood derivatives or simply by use of contaminated needles, lancets or oth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to anti-viral drugs such as Helioxanthin and its analogs. The present compounds may be used alone or in combination with other drugs for the treatment of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses. In addition, compounds according to the present invention can be used to prevent hepatoma secondary to virus infection as well as other infections or disease states which are secondary to the virus infection.

Description

Field of invention: [0001] The present invention relates to antiviral medicines such as cychroxanthin and its analog compounds. These compounds can be used alone or in combination with other drugs for the treatment of viral infections such as Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Yellow Fever Virus, Dengue Virus, Japanese Encephalitis Virus, West Nile Virus and related flaviviruses. Furthermore, the compounds of the present invention can be used for the prevention of hepatocellular carcinoma secondary to viral infection as well as other infectious or disease conditions secondary to viral infection. Background of the invention: [0002] Hepatitis B virus infection is a major health problem worldwide. HBV is the causative agent of acute and chronic forms of hepatitis. More than 300 million people worldwide are chronic HBV carriers. Generally, the human host is unaware of the infection and HBV infection results in acute hepatitis and liver injury, abdominal pain...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D317/54A61K31/11A61K31/216A61K31/222A61K31/357A61K31/36A61K31/365A61P31/12A61P31/14A61P31/20C07D307/92C07D317/70C07D407/04C07D407/14C07D493/04
CPCY10S514/935C07D493/04C07D407/14C07D317/70A61P31/12A61P31/14A61P31/20
Inventor 程扬奇周陈光傅磊高叶新叶淑芳朱竹良朱永连
Owner YALE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com